GlassScriptPhysician profile
John Paul Moses
NPI 1447737481
$24,015.38
in general payments reported to CMS, 2019-2025
24 companies · $5,058 in 2025
The $5,058 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,166 · 2022: $3,735 · 2023: $1,317 · 2024: $13K · 2025: $5,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,392 · Travel and Lodging: $2,800 · Consulting Fee: $675 · Education: $42.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,205.00 |
| Food and Beverage | $4,392.15 |
| Travel and Lodging | $2,799.83 |
| Consulting Fee | $675.00 |
| Education | $42.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $19,491.56 | 2021-2025 | Vivitrol, Aristada, Lybalvi |
| Indivior INC. | $820.78 | 2021-2025 | Sublocade |
| Abbvie INC. | $685.90 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $534.22 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $330.36 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $308.65 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $288.42 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $235.83 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $194.22 | 2025 | Auvelity |
| Gilead Sciences, INC. | $158.35 | 2021-2024 | |
| Novo Nordisk INC | $154.25 | 2021 | |
| Viiv Healthcare Company | $143.67 | 2022-2024 | Dovato |
| Amarin Pharma, INC. | $132.31 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.58 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $103.26 | 2021-2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69.64 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $43.43 | 2023-2024 | Quviviq |
| Esperion Therapeutics, INC. | $41.31 | 2021 | |
| Lilly USA, LLC | $40.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $40.07 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $25.76 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $25.48 | 2021 | |
| Pfizer INC. | $20.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.